Inovio Pharmaceuticals, Inc.
Income Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $65.3K | $217.8K | $832.0K | $10.3M | $1.8M | $7.4M | $4.1M | $30.5M |
| Cost of Revenue | — | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | $54.2M | $75.6M | $86.7M | $187.7M | $249.2M | $94.2M | $88.0M | $95.3M |
| SG&A Expense | $32.7M | $37.0M | $47.6M | $90.2M | $53.8M | $37.2M | $27.2M | $29.3M |
| Operating Income | $-86.8M | $-112.4M | $-143.9M | $-267.6M | $-301.2M | $-124.1M | $-111.1M | $-94.1M |
| Operating Margin | -132,871.3% | -51,616.9% | -17,300.3% | -2,607.4% | -16,972.3% | -1,674.2% | -2,702.1% | -308.7% |
| Interest Expense | — | — | $1.2M | $1.3M | $1.9M | $8.7M | $7.9M | $0 |
| Pretax Income | $-84.9M | $-107.3M | $-135.1M | $-277.7M | $-303.2M | $-162.9M | $-120.8M | $-94.8M |
| Income Tax Expense | $0 | $0 | $0 | $0 | $0 | $0 | $-257.3K | $2.2M |
| Net Income | $-84.9M | $-107.3M | $-135.1M | $-279.8M | $-303.7M | $-166.4M | $-119.4M | $-97.0M |
| Net Margin | -130,000.0% | -49,254.3% | -16,239.9% | -2,726.7% | -17,109.9% | -2,245.4% | -2,902.8% | -318.1% |
| EPS (Basic) | $-1.81 | $-3.95 | $-6.09 | $-14.07 | $-17.45 | $-1.07 | $-1.21 | $-1.05 |
| EPS (Diluted) | $-1.81 | $-3.95 | $-6.09 | $-14.07 | $-17.45 | $-1.07 | $-1.21 | $-1.05 |
| Shares Outstanding (Basic) | 46.9M | 27.2M | 22.2M | 19.9M | 17.4M | 155.1M | 98.7M | 92.5M |
| Shares Outstanding (Diluted) | 46.9M | 27.2M | 22.2M | 19.9M | 17.4M | 155.1M | 98.7M | 92.5M |
| Dividends Per Share | — | — | — | — | — | — | — | — |